 HAMILTON, ON and BOSTON, April 1, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has completed the acquisition of Ipsens Euronext: IPN; ADR; IPSEY intellectual property and assets related to IPN-1087. IPN-1087 is a small molecule targeting neurotensin receptor 1 NTSR1, a protein expressed on multiple solid tumor types. 